Triumph Capital Management grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,127 shares of the company’s stock after purchasing an additional 176 shares during the quarter. Triumph Capital Management’s holdings in Johnson & Johnson were worth $376,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of JNJ. Nordwand Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $785,273,000. Vanguard Group Inc. increased its stake in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. GQG Partners LLC increased its stake in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after purchasing an additional 2,547,378 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after purchasing an additional 1,805,632 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in Johnson & Johnson by 62.6% during the 1st quarter. First Trust Advisors LP now owns 2,785,312 shares of the company’s stock valued at $493,640,000 after purchasing an additional 1,072,104 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Down 0.5 %
Shares of Johnson & Johnson stock opened at $162.69 on Friday. The company has a market cap of $423.69 billion, a P/E ratio of 34.04, a PEG ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69. The firm has a fifty day moving average of $157.48 and a two-hundred day moving average of $166.96.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 94.56%.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of research reports. Raymond James cut their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday. Morgan Stanley raised their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Finally, Guggenheim initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- No, It Isn’t Time To Sell IBM Stock
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
